Connect Biopharma appointed CBIZ CPAs P.C. as its new independent registered public accounting firm on December 17, 2024, replacing PricewaterhouseCoopers Zhong Tian LLP (PwC China). The change, approved by the Audit Committee, followed PwC China's dismissal on December 10, 2024. PwC China's reports for 2022 and 2023 contained no adverse opinions or modifications.The company reported no disagreements with PwC China on accounting principles, financial statement disclosure, or auditing procedures during the fiscal years 2022, 2023, and the subsequent interim period. Connect Biopharma confirmed it had not consulted CBIZ on any accounting or auditing matters prior to the appointment.Additionally, on December 11, 2024, Zheng Wei, Ph.D. and Wubin Pan, Ph.D., MBA resigned from the company's Board of Directors as part of a previously announced leadership transition. The company plans to incorporate these changes into its Form 20-F for the year ending December 31, 2024.

Connect Biopharma appointed CBIZ CPAs P.C. as its new independent registered public accounting firm on December 17, 2024, replacing PricewaterhouseCoopers Zhong Tian LLP (PwC China). The change, approved by the Audit Committee, followed PwC China's dismissal on December 10, 2024. PwC China's reports for 2022 and 2023 contained no adverse opinions or modifications.The company reported no disagreements with PwC China on accounting principles, financial statement disclosure, or auditing procedures during the fiscal years 2022, 2023, and the subsequent interim period. Connect Biopharma confirmed it had not consulted CBIZ on any accounting or auditing matters prior to the appointment.Additionally, on December 11, 2024, Zheng Wei, Ph.D. and Wubin Pan, Ph.D., MBA resigned from the company's Board of Directors as part of a previously announced leadership transition. The company plans to incorporate these changes into its Form 20-F for the year ending December 31, 2024.